FACTREL by Hikma is mechanism of action follicular cysts are enlarged non-ovulatory follicles resulting from a malfunction of the neuroendocrine mechanism controlling follicular maturation and ovulation. First approved in 1982.
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
FACTREL (gonadorelin) is a small-molecule GnRH agonist administered by injection that induces release of endogenous luteinizing hormone (LH) to treat follicular cysts in cattle by promoting ovulation or regression of non-ovulatory follicles. It is a veterinary reproductive health product used in bovine medicine to restore normal estrous cycling and ovulation.
Product approaching loss of exclusivity with low linked job count (0) suggests minimal active commercial infrastructure and declining team investment.
MECHANISM OF ACTION Follicular cysts are enlarged non-ovulatory follicles resulting from a malfunction of the neuroendocrine mechanism controlling follicular maturation and ovulation. Exogenous administration of agents possessing luteinizing hormone (LH) activity, such as pituitary extracts or…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
With zero linked job openings and approaching LOE, FACTREL represents a legacy maintenance product with minimal career development trajectory. Roles on this portfolio are typically support-based with limited advancement into strategic product leadership.
Worked on FACTREL at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.